Recent studies have shown that oncogenic HER2 and H-Ras induced TGF-β secretion in mammary epithelial cells [36], in combining with our present results, suggesting that oncogenes may be the key switch for shifting TGF-β signaling from suppression to promotion in established cancers. The gene discussed is ERBB2; the disease is cancer.